Compass Therapeutics, Inc. (CMPX)
NASDAQ: CMPX · Real-Time Price · USD
5.37
-0.04 (-0.83%)
Apr 21, 2026, 9:41 AM EDT - Market open
Compass Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts that cover Compass Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $15.83, which forecasts a 194.79% increase in the stock price over the next year. The lowest target is $9.00 and the highest is $30.
Price Target: $15.83 (+194.79%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Compass Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 5 | 5 | 4 | 4 |
| Buy | 3 | 5 | 6 | 6 | 5 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 10 | 11 | 11 | 9 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +123.46% | Mar 24, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $30 | Strong Buy | Maintains | $30 | +458.66% | Jan 6, 2026 |
| William Blair | William Blair | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Jan 5, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Dec 3, 2025 |
| Citizens | Citizens | Buy Initiates $10 | Buy | Initiates | $10 | +86.22% | Dec 3, 2025 |
Financial Forecast
Revenue This Year
6.02M
Revenue Next Year
62.22M
from 6.02M
Increased by 934.41%
EPS This Year
-0.41
from -0.42
EPS Next Year
-0.50
from -0.41
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 41.3M | 179.4M | |||
| Avg | 6.0M | 62.2M | |||
| Low | n/a | 12.5M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | 2,881.7% | |||
| Avg | - | 934.4% | |||
| Low | - | 108.5% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.18 | -0.09 | |||
| Avg | -0.41 | -0.50 | |||
| Low | -0.61 | -1.43 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.